blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3527662

EP3527662 - NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.12.2022
Database last updated on 14.06.2024
FormerThe patent has been granted
Status updated on  24.12.2021
FormerGrant of patent is intended
Status updated on  12.09.2021
FormerExamination is in progress
Status updated on  23.07.2021
FormerGrant of patent is intended
Status updated on  06.07.2021
FormerExamination is in progress
Status updated on  21.05.2021
FormerGrant of patent is intended
Status updated on  13.04.2021
FormerExamination is in progress
Status updated on  02.07.2020
FormerRequest for examination was made
Status updated on  19.07.2019
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
CureVac AG
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
[2021/10]
Former [2019/34]For all designated states
CureVac AG
Paul-Ehrlich-Str. 15
72076 Tübingen / DE
Inventor(s)01 / THEß, Andreas
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
02 / SCHLAKE, Thomas
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
03 / PROBST, Jochen
c/o IP Department
CureVac AG
Friedrich-Miescher-Str. 15
72706 Tübingen / DE
 [2020/41]
Former [2019/34]01 / THEß, Andreas
c/o IP DEPARTMENT
CureVac AG
Paul Ehrlich Str. 15
72076 Tübingen / DE
02 / SCHLAKE, Thomas
c/o IP DEPARTMENT
CureVac AG
Paul Ehrlich Str. 15
72076 Tübingen / DE
03 / PROBST, Jochen
c/o IP DEPARTMENT
CureVac AG
Paul Ehrlich Str. 15
72076 Tübingen / DE
Representative(s)Graf von Stosch Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
[2019/34]
Application number, filing date19154524.315.02.2013
[2019/34]
Priority number, dateWO2012EP0067415.02.2012         Original published format: PCT/EP2012/000674
[2019/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3527662
Date:21.08.2019
Language:EN
[2019/34]
Type: B1 Patent specification 
No.:EP3527662
Date:26.01.2022
Language:EN
[2022/04]
Search report(s)(Supplementary) European search report - dispatched on:EP22.05.2019
ClassificationIPC:C12N15/67, A61K39/00, C12N15/63
[2019/34]
CPC:
A61K39/0011 (EP,US); A61K39/001102 (EP,US); A61K39/001104 (EP,US);
A61K39/001106 (EP,US); A61K39/001109 (EP,US); A61K39/001111 (EP,US);
A61K39/001112 (EP,US); A61K39/001113 (EP,US); A61K39/001119 (EP,US);
A61K39/001124 (EP,US); A61K39/001129 (EP,US); A61K39/001132 (EP,US);
A61K39/001134 (EP,US); A61K39/001139 (EP,US); A61K39/00114 (EP,US);
A61K39/001149 (EP,US); A61K39/00115 (EP,US); A61K39/001151 (EP,US);
A61K39/001153 (EP,US); A61K39/001156 (EP,US); A61K39/001157 (EP,US);
A61K39/001158 (EP,US); A61K39/001162 (EP,US); A61K39/001164 (EP,US);
A61K39/001166 (EP,US); A61K39/001168 (EP,US); A61K39/00117 (EP,US);
A61K39/001176 (EP,US); A61K39/001182 (EP,US); A61K39/001184 (EP,US);
A61K39/001186 (EP,US); A61K39/001188 (EP,US); A61K39/001189 (EP,US);
A61K39/00119 (EP,US); A61K39/001192 (EP,US); A61K39/001193 (EP,US);
A61K39/001194 (EP,US); A61K39/001195 (EP,US); A61K39/001197 (EP,US);
C12N15/63 (EP); C12N15/67 (EP); A61K2039/53 (EP);
A61K2039/64 (EP); C12N2830/50 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/34]
Extension statesBA30.01.2019
ME30.01.2019
TitleGerman:NUKLEINSÄURE MIT ODER ZUR CODIERUNG EINER HISTON-HAARNADELSTRUKTUR UND POLY(A)-SEQUENZ ODER EIN POLYADENYLATIONSSIGNAL ZUR ERHÖHUNG DER EXPRESSION EINES CODIERTEN TUMORANTIGENS[2019/34]
English:NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN[2019/34]
French:ACIDE NUCLÉIQUE COMPRENANT OU CODANT POUR UNE TIGE-BOUCLE D'HISTONE ET SÉQUENCE POLY(A) OU SIGNAL DE POLYADÉNYLATION POUR AUGMENTER L'EXPRESSION D'UNE PROTÉINE CODÉE[2019/34]
Examination procedure30.01.2019Examination requested  [2019/34]
18.02.2020Amendment by applicant (claims and/or description)
06.07.2020Despatch of a communication from the examining division (Time limit: M04)
16.11.2020Reply to a communication from the examining division
14.04.2021Communication of intention to grant the patent
21.05.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.07.2021Communication of intention to grant the patent
21.07.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.09.2021Communication of intention to grant the patent
20.12.2021Fee for grant paid
20.12.2021Fee for publishing/printing paid
20.12.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13704551.4  / EP2814961
EP16001897.4  / EP3178488
Opposition(s)27.10.2022No opposition filed within time limit [2023/01]
Fees paidRenewal fee
30.01.2019Renewal fee patent year 03
30.01.2019Renewal fee patent year 04
30.01.2019Renewal fee patent year 05
30.01.2019Renewal fee patent year 06
30.01.2019Renewal fee patent year 07
30.12.2019Renewal fee patent year 08
17.02.2021Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.02.2013
AL26.01.2022
AT26.01.2022
CY26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
MK26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SI26.01.2022
SK26.01.2022
SM26.01.2022
TR26.01.2022
IE15.02.2022
LU15.02.2022
BE28.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
[2024/29]
Former [2024/25]HU15.02.2013
AL26.01.2022
AT26.01.2022
CY26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
MK26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SI26.01.2022
SK26.01.2022
SM26.01.2022
IE15.02.2022
LU15.02.2022
BE28.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2024/23]AL26.01.2022
AT26.01.2022
CY26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
MK26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SI26.01.2022
SK26.01.2022
SM26.01.2022
IE15.02.2022
LU15.02.2022
BE28.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2024/20]AL26.01.2022
AT26.01.2022
CY26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SI26.01.2022
SK26.01.2022
SM26.01.2022
IE15.02.2022
LU15.02.2022
BE28.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2023/10]AL26.01.2022
AT26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SI26.01.2022
SK26.01.2022
SM26.01.2022
IE15.02.2022
LU15.02.2022
BE28.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2023/09]AL26.01.2022
AT26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SK26.01.2022
SM26.01.2022
IE15.02.2022
LU15.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2023/01]AL26.01.2022
AT26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SK26.01.2022
SM26.01.2022
LU15.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2022/49]AT26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SK26.01.2022
SM26.01.2022
LU15.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2022/48]AT26.01.2022
CZ26.01.2022
DK26.01.2022
EE26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SM26.01.2022
LU15.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2022/47]AT26.01.2022
DK26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
MC26.01.2022
NL26.01.2022
PL26.01.2022
RO26.01.2022
RS26.01.2022
SE26.01.2022
SM26.01.2022
LU15.02.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2022/46]AT26.01.2022
DK26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
NL26.01.2022
PL26.01.2022
RS26.01.2022
SE26.01.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2022/42]AT26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
NL26.01.2022
PL26.01.2022
RS26.01.2022
SE26.01.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
IS26.05.2022
PT26.05.2022
Former [2022/39]AT26.01.2022
FI26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
NL26.01.2022
PL26.01.2022
RS26.01.2022
SE26.01.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
PT26.05.2022
Former [2022/36]AT26.01.2022
HR26.01.2022
LT26.01.2022
LV26.01.2022
NL26.01.2022
PL26.01.2022
RS26.01.2022
SE26.01.2022
BG26.04.2022
NO26.04.2022
GR27.04.2022
PT26.05.2022
Former [2022/35]HR26.01.2022
LT26.01.2022
NL26.01.2022
RS26.01.2022
SE26.01.2022
BG26.04.2022
NO26.04.2022
PT26.05.2022
Former [2022/34]LT26.01.2022
NL26.01.2022
NO26.04.2022
PT26.05.2022
Former [2022/33]LT26.01.2022
NL26.01.2022
NO26.04.2022
Former [2022/30]NL26.01.2022
Documents cited:Search[A]WO9842856  (ENZO THERAPEUTICS INC A FULLY [US]) [A] 3,4,15,17-21,23,24 * example 2 *;
 [A]WO2006008154  (CUREVAC GMBH [DE], et al) [A] 18 * example 1; claims 1-20 *;
 [A]WO2010132867  (IRX THERAPEUTICS INC [US], et al) [A] 3,4,16-21,23,24 * paragraph [0101] - paragraph [0104] *;
 [A]WO2011069529  (CUREVAC GMBH [DE], et al) [A] 18 * page 30 - page 54 *;
 [XP]WO2012019630  (CUREVAC GMBH [DE], et al) [XP] 1,2,4-14,16,18-24 * page 28 - page 34; claims 1-7,11-15 *;
 [XI]  - COLLART D ET AL, "A human histone H2B.1 variant gene, located on chromosome 1, ultilizes alternative 3' end processing", JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, (199212), vol. 50, doi:10.1002/JCB.240500406, ISSN 0730-2312, pages 374 - 385, XP002956108 [X] 1,2,5,6,8,9,11,14,15,17 * page 378; figure 1 * [I] 7,10,12,13,22

DOI:   http://dx.doi.org/10.1002/jcb.240500406
 [A]  - KATO M ET AL, "Histone H2B as an antigen recognized by lung cancer-specific human monoclonal antibody HB4C5.", HUMAN ANTIBODIES AND HYBRIDOMAS APR 1991, (199104), vol. 2, no. 2, ISSN 0956-960X, pages 94 - 101, XP009168615 [A] 1 * abstract *
 [A]  - J E RUSSEL ET AL, "The stability of human beta-globin mRNA is dependent on structural determinants positioned within its 3' untranslated region", BLOOD, (1996), vol. 87, ISSN 0006-4971, pages 5314 - 5323, XP055043656 [A] 1-9 * page 5322 *
 [AD]  - DAVILA LOPEZ, M.; SAMUELSSON, T., RNA, (2008), vol. 14, no. 1, pages 1 - 10, XP002686760 [AD] 1-9 * page 4 - page 5; figures 3,4; table 1 *

DOI:   http://dx.doi.org/10.1261/rna.782308
 [A]  - DANIEL J. BATTLE ET AL, "The stem-loop binding protein forms a highly stable and specific complex with the 3' stem-loop of histone mRNAs", RNA, (200101), vol. 7, no. 1, doi:10.1017/S1355838201001820, ISSN 1355-8382, pages 123 - 132, XP055043659 [A] 1-9 * page 129 - page 130; figure 5 *

DOI:   http://dx.doi.org/10.1017/S1355838201001820
 [A]  - TAKASHI NARITA ET AL, "NELF Interacts with CBC and Participates in 3' End Processing of Replication-Dependent Histone mRNAs", MOLECULAR CELL, (200705), vol. 26, no. 3, doi:10.1016/j.molcel.2007.04.011, ISSN 1097-2765, pages 349 - 365, XP055059018 [A] 4 * figure 4 *

DOI:   http://dx.doi.org/10.1016/j.molcel.2007.04.011
by applicantWO0112824
 WO02098443
 WO2007036366
    - MEYER, S.; C. TEMME, Crit Rev Biochem Mol Biol, (20040000), vol. 39, no. 4, pages 197 - 216
    - MICHEL, Y. M.; D. PONCET et al., J Biol Chem, (20000000), vol. 275, no. 41, pages 32268 - 76
    - DOMINSKI, Z; W. F. MARZLUFF, Gene, (20070000), vol. 396, no. 2, pages 373 - 90
    - DAVILA LOPEZ, M.; SAMUELSSON, T., RNA, (20080000), vol. 14, no. 1, pages 1 - 10
    - CHODCHOY, N.; N. B. PANDEY et al., Mol Cell Biol, (19910000), vol. 11, no. 1, pages 497 - 509
    - PANDEY, N. B. et al., Molecular and Cellular Biology, (19940000), vol. 14, no. 3, pages 1709 - 1720
    - WILLIAMS, A. S.; MARZLUFF, W. F., Nucleic Acids Research, (19950000), vol. 23, no. 4, pages 654 - 662
    - SANCHEZ, R; W. F. MARZLUFF, Mol Cell Biol, (20040000), vol. 24, no. 6, pages 2513 - 25
    - WHITELAW, E. et al., Nucleic Acids Research, (19860000), vol. 14, no. 17, pages 7059 - 7070
    - PANDEY, N. B.; MARZLUFF, W. F., Molecular and Cellular Biology, (19870000), vol. 7, no. 12, pages 4557 - 4559
    - PANDEY, N. B. et al., Nucleic Acids Research, (19900000), vol. 18, no. 11, pages 3161 - 3170
    - LUSCHER, B., Proc. Natl. Acad. Sci. USA, (19850000), vol. 82, no. 13, pages 4389 - 4393
    - STAUBER, C et al., EMBO J, (19860000), vol. 5, no. 12, pages 3297 - 3303
    - WAGNER, E. J et al., Mol Cell, (20070000), vol. 28, no. 4, pages 692 - 9
    - GALLIE, D. R.; LEWIS, N. J.; MARZLUFF, W. F, Nucleic Acids Research, (19960000), vol. 24, no. 10, pages 1954 - 1962
    - AKASHI, Curr. Opin. Genet. Dev., (20010000), vol. 11, no. 6, pages 660 - 666
    - HOLCIK et al., Proc. Natl. Acad. Sci. USA, (19970000), vol. 94, pages 2410 - 2414
    - "GenBank", Database accession no. U26404
    - LAI et al., Development, (19950000), vol. 121, pages 2349 - 2360
    - "GenBank", Database accession no. X65300
    - "GenBank", Database accession no. X65327
    - KARLIN et al., PNAS USA, (19930000), vol. 90, pages 5873 - 5877
    - ALTSCHUL et al., Nucleic Acids Res, (19970000), vol. 25, pages 3389 - 3402
    - DAVILA LOPEZ, M.; SAMUELSSON, T, RNA (New York, N.Y., (20080000), vol. 14, no. 1, pages 1 - 10
    - DAVILA LOPEZ, M.; SAMUELSSON, T, RNA, (20080000), vol. 14, no. 1, pages 1 - 10
    - CAKMAKCI et al., Molecular and Cellular Biology, (20080000), vol. 28, no. 3, pages 1182 - 1194
    - THISTED et al., The Journal of Biological Chemistry, (20010000), vol. 276, no. 20, pages 17484 - 17496
    - MAKEYEV, Genomics, (20000000), vol. 67, no. 3, pages 301 - 316
    - CHKHEIDZE et al., Molecular and Cellular Biology, (19990000), vol. 19, no. 7, pages 4572 - 4581
    - BABENDURE, RNA, (20060000), vol. 12, no. 5, pages 851 - 861
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.